Johnson & Johnson to fall short of vaccine doses promised by end of month

Johnson & Johnson expects to fall far short of its commitment to deliver 10 million doses of its COVID-19 vaccine by the end of February, with under 4 million to be ready to ship after a hoped-for emergency use authorization from the Food and Drug Administration. 

The disclosure of the shortfall by Johnson & Johnson is the first public measure of exactly how far the drug company has fallen behind its production goals. Johnson & Johnson promised to deliver another 25 million by the end of March.

“We will have 20 million doses of the vaccine to be made available by the end of March and we’re prepared to ship, immediately upon emergency use authorization, nearly 4 million doses of our vaccine,” Dr. Richard Nettles, Johnson & Johnson subsidiary Janssen’s vice president of medical affairs, told a House Energy & Commerce Committee hearing Tuesday. 

He said the company remains “confident in our plans to deliver 100 million” doses by the end of June.

As a single-dose vaccine that can be stored at standard refrigerator temperatures for three months, Johnson & Johnson’s candidate had been heralded as a key advance in the U.S. vaccine effort despite its slightly lower efficacy, compared

View Source